PriceTargets.com logo

9 Meters Biopharma - NMTR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.18
  • Forecasted Upside: 3,196.64%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.34 As of 03/24/2023 01:00 AM ET
▲ +0.03 (2.29%)

This chart shows the closing price for NMTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 9 Meters Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NMTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NMTR

Analyst Price Target is $44.18
▲ +3,196.64% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for 9 Meters Biopharma in the last 3 months. The average price target is $44.18, with a high forecast of $100.00 and a low forecast of $1.70. The average price target represents a 3,196.64% upside from the last price of $1.34.

This chart shows the closing price for NMTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in 9 Meters Biopharma. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2023Brookline Capital ManagementReiterated RatingBuyLow
3/20/2023Truist FinancialDowngradeBuy ➝ HoldLow
3/16/2023CitigroupLower Target$2.70 ➝ $1.70Low
2/13/2023CitigroupInitiated CoverageNeutralLow
11/10/2022BMO Capital MarketsLower TargetOutperform$57.00 ➝ $35.00Low
10/25/2022Brookline Capital ManagementReiterated RatingBuyLow
10/3/2022Brookline Capital ManagementReiterated RatingBuyLow
9/27/2022OppenheimerBoost TargetOutperform$80.00 ➝ $100.00Low
7/1/2022Maxim GroupDowngradeBuy ➝ HoldLow
6/22/2022Truist FinancialLower TargetBuy$100.00 ➝ $40.00Low
6/22/2022BMO Capital MarketsLower TargetOutperform$100.00 ➝ $60.00Low
7/8/2021BMO Capital MarketsInitiated CoverageOutperform$100.00High
6/4/2021CitigroupInitiated CoverageBuyMedium
3/25/2021Brookline Capital ManagementReiterated RatingBuyHigh
3/25/2021Brookline Capital AcquisitionReiterated RatingBuy$120.00Medium
3/25/2021Maxim GroupInitiated CoverageBuy$60.00Medium
1/28/2021OppenheimerInitiated CoverageOutperform$120.00High
1/5/2021William BlairReiterated RatingBuyN/A
10/30/2020Maxim GroupInitiated CoverageBuyMedium
9/24/2020William BlairReiterated RatingBuyMedium
9/23/2020William BlairInitiated CoverageOutperform$100.00High
9/21/2020HC WainwrightReiterated RatingBuyLow
8/18/2020Brookline Capital ManagementInitiated CoverageBuy$100.00High
6/30/2020SunTrust BanksInitiated CoverageBuy$100.00High
10/11/2018Raymond JamesInitiated CoverageMarket PerformN/A
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

9 Meters Biopharma logo
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.
Read More

Today's Range

Now: $1.34
Low: $1.31
High: $1.34

50 Day Range

MA: $1.90
Low: $1.31
High: $2.61

52 Week Range

Now: $1.34
Low: $1.00
High: $13.20

Volume

15,651 shs

Average Volume

73,675 shs

Market Capitalization

$17.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of 9 Meters Biopharma?

The following Wall Street analysts have issued stock ratings on 9 Meters Biopharma in the last twelve months: BMO Capital Markets, Brookline Capital Management, Citigroup Inc., Maxim Group, Oppenheimer Holdings Inc., and Truist Financial Co..
View the latest analyst ratings for NMTR.

What is the current price target for 9 Meters Biopharma?

4 Wall Street analysts have set twelve-month price targets for 9 Meters Biopharma in the last year. Their average twelve-month price target is $44.18, suggesting a possible upside of 3,196.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting NMTR will reach $100.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $1.70 for 9 Meters Biopharma in the next year.
View the latest price targets for NMTR.

What is the current consensus analyst rating for 9 Meters Biopharma?

9 Meters Biopharma currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NMTR will outperform the market and that investors should add to their positions of 9 Meters Biopharma.
View the latest ratings for NMTR.

What other companies compete with 9 Meters Biopharma?

Other companies that are similar to 9 Meters Biopharma include Comera Life Sciences, Chemomab Therapeutics, Adamis Pharmaceuticals, Infinity Pharmaceuticals and NeuroSense Therapeutics. Learn More about companies similar to 9 Meters Biopharma.

How do I contact 9 Meters Biopharma's investor relations team?

9 Meters Biopharma's physical mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company's listed phone number is (919) 275-1933 and its investor relations email address is [email protected] The official website for 9 Meters Biopharma is www.9meters.com. Learn More about contacing 9 Meters Biopharma investor relations.